Seeking Alpha

More on Vivus earnings

  • Vivus (VVUS) Q2 comes in below estimates.
  • Net product revenue was $5.5M, versus a flatline last year.
  • Net losses increased Y/Y, primarily due to increased SG&A expenses related to commercialization activities for Qsymia.
  • Approximately 81K Qsymia prescriptions were dispensed during the quarter, of which approximately 24K were dispensed under the Free Trial Offer.
  • All of these prescriptions were dispensed through the certified mail order home delivery system.
  • Shares unchanged AH.
Comments (1)
  • user418
    , contributor
    Comments (196) | Send Message
    Short VVUS and go long ARNA !!!
    6 Aug 2013, 05:37 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: